<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Antibody-mediated disorders of <z:hpo ids='HP_0011874'>heparin-induced thrombocytopenia</z:hpo> and <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome have remarkably similar clinical presentations, both of which can progressively result in severe vascular and thrombotic disorders </plain></SENT>
<SENT sid="1" pm="."><plain>We hypothesized that the mechanism of platelet activation as occurs in <z:hpo ids='HP_0011874'>heparin-induced thrombocytopenia</z:hpo> may also occur in <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome particularly at the vascular wall, that endothelial injury may be similar in <z:hpo ids='HP_0011874'>heparin-induced thrombocytopenia</z:hpo> and <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome, and that these alterations may be caused by related antibodies </plain></SENT>
<SENT sid="2" pm="."><plain>Antibody titers and vascular endothelial damage in patients with <z:hpo ids='HP_0011874'>heparin-induced thrombocytopenia</z:hpo> and <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome were studied in plasma samples collected from <z:mpath ids='MPATH_458'>normals</z:mpath> (n = 17), <z:hpo ids='HP_0011874'>heparin-induced thrombocytopenia</z:hpo> patients (n = 15), <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome patients (n = 30), and patients clinically diagnosed with <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome and <z:hpo ids='HP_0011874'>heparin-induced thrombocytopenia</z:hpo> (n = 8) </plain></SENT>
<SENT sid="3" pm="."><plain>Diagnosis of <z:hpo ids='HP_0011874'>heparin-induced thrombocytopenia</z:hpo> was confirmed by <z:chebi fb="32" ids="36927">14C</z:chebi>-<z:chebi fb="19" ids="28790">serotonin</z:chebi> release assay or positive antiheparin-platelet factor 4 antibody titer, and <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome was confirmed by positive anti-beta 2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> (GP) 1/<z:chebi fb="0" ids="28494">cardiolipin</z:chebi> (IgG or IgM) antibody titer </plain></SENT>
<SENT sid="4" pm="."><plain>The antiheparin-platelet factor 4 antibody was not detected in any patient with <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome </plain></SENT>
<SENT sid="5" pm="."><plain>Patients with <z:hpo ids='HP_0011874'>heparin-induced thrombocytopenia</z:hpo> did not have elevated IgG anti-beta 2-GP1 titers, but three (20%) patients had low-positive IgM anti-beta 2-GP1 titers </plain></SENT>
<SENT sid="6" pm="."><plain>The endothelial damage markers of soluble thrombomodulin, soluble P-selectin (p &lt; 0.05 vs. <z:mpath ids='MPATH_458'>normal</z:mpath>), plasminogen activator inhibitor-1 and tissue factor were elevated in <z:hpo ids='HP_0011874'>heparin-induced thrombocytopenia</z:hpo> and <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome patients </plain></SENT>
<SENT sid="7" pm="."><plain>The soluble E-selectin was elevated only in the patients with both <z:hpo ids='HP_0011874'>heparin-induced thrombocytopenia</z:hpo> and <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome (p &lt; 0.05 vs. <z:mpath ids='MPATH_458'>normal</z:mpath>) </plain></SENT>
<SENT sid="8" pm="."><plain>Levels of soluble L-selectin and <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor were not different from <z:mpath ids='MPATH_458'>normals</z:mpath> </plain></SENT>
<SENT sid="9" pm="."><plain>The pathogenesis of <z:hpo ids='HP_0011874'>heparin-induced thrombocytopenia</z:hpo> and <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome appears to be due to two distinct antibodies but associated with similar damage to the vascular endothelium in both diseases </plain></SENT>
</text></document>